Handbook of Therapeutic Antibodies
Technologies, Emerging Developments and Approved Therapeutics
(Sprache: Englisch)
This most comprehensive reference source for the development, production and therapeutic application of antibodies is now available as a competitively priced softcover edition. It includes general chapters presenting established technologies and clinical...
Jetzt vorbestellen
versandkostenfrei
Buch (Kartoniert)
225.20 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
- Ratenzahlung möglich
Produktdetails
Produktinformationen zu „Handbook of Therapeutic Antibodies “
This most comprehensive reference source for the development, production and therapeutic application of antibodies is now available as a competitively priced softcover edition. It includes general chapters presenting established technologies and clinical applications, chapters on emerging technologies, new therapeutic concepts, and clinical studies and detailed and specific information about currently approved therapeutic antibodies, including clinical data.
A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic.
A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic.
Klappentext zu „Handbook of Therapeutic Antibodies “
This most comprehensive reference source for the development, production and therapeutic application of antibodies is now available as a competitively priced softcover edition. It includes general chapters presenting established technologies and clinical applications, chapters on emerging technologies, new therapeutic concepts, and clinical studies and detailed and specific information about currently approved therapeutic antibodies, including clinical data.Nearly 100 international experts and researchers from academia, industry, and such regulating bodies as the FDA have contributed to this work. Includes are also information on intellectual property issues, hardly available elsewhere.
A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic.
From the foreword by Mark Glassy, Chairman & Professor, The Rajko Medenica Research Foundation, and Chief Executive Officer, Shantha West, Inc., San Diego, CA, USA:
"After more than a century of intense analysis, antibodies continue to amaze and inspire. This Handbook of Therapeutic Antibodies is not just an assembly of articles but rather a state-of-the-art comprehensive compendium, which will appeal to all those interested in antibodies, whether from academia, industry, or the clinic. It is an unrivalled resource which shows how mature the antibody field has become and how precisely the antibody molecule can be manipulated and utilized."
Stefan Dübel studied biology at the universities of Mainz and Heidelberg, initially concentrating on developmental biology. From 1989 onwards he carried out pioneering work on antibody phage display and antibody libraries with randomised CDRs. Further work focussed on antibody fusion proteins and improvements of antibody phage display. Currently he is Director of the Department of Biotechnology at the Technical University of Braunschweig and coordinator of the 'Antibody Factory' within the German National Genome Research
... mehr
Network. Stefan Dübel has co-authored a number of textbooks, about 90 publications and 15 patents in the field of recombinant antibodies and phage display.
... weniger
Inhaltsverzeichnis zu „Handbook of Therapeutic Antibodies “
Section I: TechnologiesForeword
A Greeting from the Editor
PART 0: INTRODUCTION
Therapeutic Antibodies - From Past to Future
PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE
Selection strategies I: Monoclonal Antibodies
Selection strategies II: Antibody Phage Display
Selection strategies III: Transgenic Mice
Bioinformatic Tools for Antibody Engineering
Molecular Engineering I: Humanization
Molecular Engineering II: Affinity Maturation
Molecular Engineering III: Fc Engineering
PART II: THE WAY INTO THE CLINIC
Production and Downstream Processing
Pharmaceutical Formulation and Clinical Application
Immunogenicity of Antibody Therapeutics
Regulatory Considerations
Intellectual Property Issues
Section II: Emerging Developments
PART III: BEYOND IGG: MODIFIED ANTIBODIES
Immunoscintigraphy and Radioimmunotherapy
Bispecific Antibodies
Immunotoxins / Targeted RNases
PART IV: EMERGING CONCEPTS
Automation of Selection and Engineering
Emerging Technologies for Antibody Selection
Emerging Alternative Production Systems
Non-Antibody Scaffolds
Emerging Therapeutic Concepts I: ADEPT
Emerging Therapeutic Concepts II: Nanotechnology
Emerging Therapeutic Concepts III:Cell-bound antibodies
Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies
PART V: ONGOING CLINICAL STUDIES:
Antibodies in Phase I/II/III: Cancer Therapy
Antibodies in Phase I/II/III: Targeting TNF
Section III: APPROVED THERAPEUTICS
Adalimumab (Humira)
Alemtuzumab (Mabcampath)
Bevacizumab (Avastin)
Cetuximab (Erbitux)
Efalizumab (Raptiva)
Fanolesomab/Technetium99m (Neutrospec)
Gemtuzumab Ozogamicin (Mylotarg)
Infliximab (Remicade)
Muromonab (Orthoclone)
Natalizumab (Tysabri)
Omalizumab (Xolair)
Palivizumab (Synagis)
Rituximab (Rituxan)
Trastuzumab (Herceptin)
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab
Autoren-Porträt
Stefan Dübel received his PhD at the Center for Molecular Biology Heidelberg and spent his post-doc at the German Cancer Research Center with research on the development of antibody display libraries. In the following years, he substantially participated in the invention of recombinant antibody phage display technology, as well as other recombinant antibody technologies and the development of various antibody fusion proteins. In 1996, he moved to the University of Heidelberg to establish the antibody engineering group at the Institute of Molecular Genetics. After holding a group leader position at the University of Heidelberg from 1996, Stefan Dübel went to the Biological Faculty of the Technical University of Braunschweig as a full professor in 2002. Here, he currently serves as head of the Department of Biotechnology in Braunschweig and managing director of the Institute of Biochemistry and Biotechnology. He has co-authored more than 90 scientific papers, 17 patents, as well as two acknowledged textbooks in the field of recombinant antibodies. He is also board member of scientific journals and the biotech industry.
Bibliographische Angaben
- 2010, XLVI, 1204 Seiten, 100 farbige Abbildungen, Maße: 17,4 x 24,6 cm, Kartoniert (TB), Englisch
- Herausgegeben: Stefan Dübel
- Verlag: Wiley-VCH
- ISBN-10: 3527329021
- ISBN-13: 9783527329021
- Erscheinungsdatum: 30.07.2010
Sprache:
Englisch
Rezension zu „Handbook of Therapeutic Antibodies “
"...Das dreibändige Werk ist wirklich ausgesprochen gut gelungen...Jedem, der sich mit Antikörpern beschäftigt, ist dieses Buch wärmstens zu empfehlen." Pharmazie in unserer Zeit, 09/2007
Kommentar zu "Handbook of Therapeutic Antibodies"
Schreiben Sie einen Kommentar zu "Handbook of Therapeutic Antibodies".
Kommentar verfassen